These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 34468898)

  • 1. Drug repositioning for anti-tuberculosis drugs: an in silico polypharmacology approach.
    Madugula SS; Nagamani S; Jamir E; Priyadarsinee L; Sastry GN
    Mol Divers; 2022 Jun; 26(3):1675-1695. PubMed ID: 34468898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A QSAR and molecular modelling study towards new lead finding: polypharmacological approach to Mycobacterium tuberculosis.
    Janardhan S; John L; Prasanthi M; Poroikov V; Narahari Sastry G
    SAR QSAR Environ Res; 2017 Oct; 28(10):815-832. PubMed ID: 29183232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polypharmacological repurposing approach identifies approved drugs as potential inhibitors of Mycobacterium tuberculosis.
    Singh J; Quadir N; Vashishtha S; Chakraborty A; Alam A; Kundu B; Ahmad U; Sundar D; Ehtesham NZ; Hasnain SE
    Biochem J; 2023 Jul; 480(14):1079-1096. PubMed ID: 37306466
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Jagadeb M; Rath SN; Sonawane A
    J Biomol Struct Dyn; 2019 Aug; 37(13):3388-3398. PubMed ID: 30132739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Repurposing Approach for Uncovering the Anti-Tubercular Activity of FDA-Approved Drugs with Potential Multi-Targeting Profiles.
    Battah B; Chemi G; Butini S; Campiani G; Brogi S; Delogu G; Gemma S
    Molecules; 2019 Nov; 24(23):. PubMed ID: 31795400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and antimycobacterial evaluation of novel adamantane and adamantanol analogues effective against drug-resistant tuberculosis.
    Alsayed SSR; Lun S; Payne A; Bishai WR; Gunosewoyo H
    Bioorg Chem; 2021 Jan; 106():104486. PubMed ID: 33276981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multidrug efflux protein in Mycobacterium tuberculosis; tap as a potential drug target for drug repurposing.
    Dwivedi M; Mukhopadhyay S; Yadav S; Dubey KD
    Comput Biol Med; 2022 Jul; 146():105607. PubMed ID: 35617724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prospects for development of new antituberculous drugs].
    Tomioka H
    Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recognizing drug targets using evolutionary information: implications for repurposing FDA-approved drugs against Mycobacterium tuberculosis H37Rv.
    Ramakrishnan G; Chandra NR; Srinivasan N
    Mol Biosyst; 2015 Dec; 11(12):3316-31. PubMed ID: 26429199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polypharmacology-Driven Discovery and Design of Highly Selective, Dual and Multitargeting Inhibitors of
    Amandy FV; Neri GLL; Manzano JAH; Go AD; Macabeo APG
    Curr Drug Targets; 2024; 25(9):620-634. PubMed ID: 38859782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atosiban and Rutin exhibit anti-mycobacterial activity - An integrated computational and biophysical insight toward drug repurposing strategy against Mycobacterium tuberculosis targeting its essential enzyme HemD.
    Sharma R; Muthu SA; Agarwal M; Mehto NK; Pahuja I; Grover A; Dwivedi VP; Ahmad B; Grover S
    Int J Biol Macromol; 2023 Dec; 253(Pt 6):127208. PubMed ID: 37816464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential anti-TB investigational compounds and drugs with repurposing potential in TB therapy: a conspectus.
    Adeniji AA; Knoll KE; Loots DT
    Appl Microbiol Biotechnol; 2020 Jul; 104(13):5633-5662. PubMed ID: 32372202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Recent progress in mycobacteriology].
    Okada M; Kobayashi K
    Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repurposed drug candidates for antituberculosis therapy.
    An Q; Li C; Chen Y; Deng Y; Yang T; Luo Y
    Eur J Med Chem; 2020 Apr; 192():112175. PubMed ID: 32126450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of antitubercular 2,4-diphenyl-1H-imidazoles from chemical library repositioning and rational design.
    Pieroni M; Wan B; Zuliani V; Franzblau SG; Costantino G; Rivara M
    Eur J Med Chem; 2015 Jul; 100():44-9. PubMed ID: 26071857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multitargeting Compounds: A Promising Strategy to Overcome Multi-Drug Resistant Tuberculosis.
    Stelitano G; Sammartino JC; Chiarelli LR
    Molecules; 2020 Mar; 25(5):. PubMed ID: 32182964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of novel multitarget antitubercular inhibitors against mycobacterial peptidoglycan biosynthetic Mur enzymes by structure-based virtual screening.
    Kumari M; Subbarao N
    J Biomol Struct Dyn; 2022 Nov; 40(18):8185-8196. PubMed ID: 33826470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.